Hemophilia Spin Off Hemophilia Spin Off (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Feb. 01, 2017
Assets and Liabilities Distributed to Bioverativ [Line Items]
Other	$ 90.0	$ 87.9
Cost of sales	384.6	313.0
Product, net	2,380.1	2,309.4
Hemophilia products
Assets and Liabilities Distributed to Bioverativ [Line Items]
Product, net	$ 74.4	$ 182.7
Bioverativ
Assets and Liabilities Distributed to Bioverativ [Line Items]
Term of Bioverativ transaction services agreement	12 months
Term of Bioverativ manufacturing and supply agreement	5 years
Cash			$ 302.7
Other	$ 3.1
Cost of sales	$ 2.9